In June of 2023, a drug developed by Insilico Medicine for treating idiopathic pulmonary fibrosis, a lung disease, began clinical trials with human patients. The use of AI in the field of drug discovery is promising as it has the potential to suggest new treatments that researchers might not have considered otherwise.
Recently, Alex Zhavoronkov, the Head of the LongeVC Scientific Advisory Board, shared more details about his and Insilico Medicine's journey in an in-depth MIT Technology Review article written by Antonio Regalado.
You can read it here.
Recently, Alex Zhavoronkov, the Head of the LongeVC Scientific Advisory Board, shared more details about his and Insilico Medicine's journey in an in-depth MIT Technology Review article written by Antonio Regalado.
You can read it here.